<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960581</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI T001</org_study_id>
    <nct_id>NCT02960581</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGT121 Monoclonal Antibody (mAb) in HIV-uninfected and HIV-infected Adults</brief_title>
  <official_title>A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGT121 Monoclonal Antibody (mAb) in HIV-uninfected and HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy. PGT121 mAb is a
      recombinant human IgG1 monoclonal antibody that targets a V3 glycan-dependent epitope region
      of the HIV envelope protein. PGT121 mAb was chosen for this study because it is potent,
      neutralizes a wide array of HIV viruses, and can prevent and treat simian-human
      immunodeficiency virus (SHIV) in rhesus monkeys.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with PGT121 mAb related AEs and SAEs</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>The investigators will measure the following endpoints to evaluate the safety and tolerability of PGT121 mAb in HIV-uninfected and HIV-infected adults:
Proportion of participants with moderate or greater reactogenicity (e.g., solicited adverse events) for 3 days following IV infusion of PGT121 mAb.
Proportion of participants with moderate or greater and/or PGT121 mAb-related unsolicited adverse events (AEs), including safety laboratory (biochemical, hematological) parameters, following IV infusion of PGT121 mAb for the first 56 days post administration of Investigational Product.
Proportion of participants with PGT121 mAb-related serious adverse events (SAEs) throughout the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of viral load and/or ART on PGT121 disposition elimination half-life (t1/2)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma HIV-1 RNA levels from baseline (mean of pre-entry and entry values)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of viral load and/or ART on PGT121 disposition clearance (CL/F)</measure>
    <time_frame>6 Months post infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of viral load and/or ART on PGT121 disposition volume of distribution (Vz/F)</measure>
    <time_frame>6 months post infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of viral load and/or ART on PGT121 disposition total exposure</measure>
    <time_frame>6 months post infusion</time_frame>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected on ART, (&lt;50 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected on ART, (&lt;50 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected on ART, (&lt;50 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121</intervention_name>
    <description>3mg/kg administered by IV Infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121</intervention_name>
    <description>10mg/kg administered by IV infusion</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121</intervention_name>
    <description>30mg/kg administered by IV infusion</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121</intervention_name>
    <description>30mg/kg administered by IV infusion
Placebo: None</description>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121</intervention_name>
    <description>10mg/kg administered by IV infusion
Placebo: None</description>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_label>Group 11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121</intervention_name>
    <description>3mg/kg administered by IV infusion
Placebo: None</description>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_label>Group 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (0.9% Sodium Chloride Injection USP (Saline))</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 Inclusion Criteria:

          -  Willing to maintain low risk behavior for HIV infection

        Group 1 Exclusion Criteria:

          -  confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease
             and clinically significant laboratory abnormalities

        Group 2 Inclusion Criteria:

          -  HIV-infected males or females on a stable antiretroviral regimen with HIV-1 RNA plasma
             level &lt;50 copies/ml, CD4 cell count &gt; 300 cells/uL and CD4 nadir &gt; 200 cell/uL

        Group 2 Exclusion Criteria:

          -  history of AIDS-defining illness, significant acute or chronic medical condition other
             than HIV infection, and clinically significant laboratory abnormalities

        Group 3 Inclusion Criteria:

          -  HIV-infected males or females not on antiretroviral therapy for &gt; 6 month with
             detectable HIV-1 RNA plasma level between 100 and 100,000 copies/ml, CD4 cell count &gt;
             300 cells/uL and CD4 nadir &gt; 200 cell/uL

        Group 3 Exclusion Criteria:

          -  history of AIDS-defining illness, significant acute or chronic medical condition other
             than HIV infection, and clinically significant laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Stephenson, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Juelg, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ragon Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://iavi.org</url>
    <description>International AIDS Vaccine Initiative</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

